Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2019

01-02-2019 | Hepatobiliary Tumors

Hepatic Angiosarcoma: A Multi-institutional, International Experience with 44 Cases

Authors: Gregory C. Wilson, MD, Nuria Lluis, MD, Michael A. Nalesnik, MD, Aziza Nassar, MD, Teresa Serrano, MD, Emilio Ramos, MD, Michael Torbenson, MD, Horacio J. Asbun, MD, David A. Geller, MD

Published in: Annals of Surgical Oncology | Issue 2/2019

Login to get access

Abstract

Background

Hepatic angiosarcoma is a rare primary liver tumor. The aim of this current study was to evaluate the presentation and treatment outcomes in a modern cohort.

Methods

This was a retrospective, multi-institutional, observational study of patients with histopathologic diagnoses of primary hepatic angiosarcoma from four institutions. Clinicopathologic characteristics, treatments, and patient outcomes were examined.

Results

Forty-four patients with hepatic angiosarcoma were identified. Patients were predominantly Caucasian and presented at a median age of 63.7 years; 81.4% of patients had bilobar disease and 37.2% had metastatic disease at the time of presentation. Only 10 patients underwent surgical resection. Median overall survival for the entire cohort was 5.8 months (interquartile range 1.9–16.4), and 1-, 3-, and 5-year actual survival was 30.0%, 8.1%, and 5.6%, respectively. There were only two 5-year survivors, both of whom presented with localized disease and underwent curative resection.

Conclusion

The prognosis for hepatic angiosarcoma remains quite poor. Surgical resection for localized disease results in the best outcomes. Unfortunately, current imaging modalities are often non- diagnostic, and most patients are unresectable at the time of presentation.
Literature
1.
Hamilton SRA, Lauri A. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000.
2.
Falk H, Herbert J, Crowley S, et al. Epidemiology of hepatic angiosarcoma in the United States: 1964–1974. Environ Health Perspect. 1981;41:107–13.CrossRefPubMedPubMedCentral
3.
Chaudhary P, Bhadana U, Singh RA, Ahuja A. Primary hepatic angiosarcoma. Eur J Surg Oncol. 2015;41(9):1137–43.CrossRefPubMed
4.
Groeschl RT, Miura JT, Oshima K, Gamblin TC, Turaga KK. Does histology predict outcome for malignant vascular tumors of the liver? J Surg Oncol. 2014;109(5):483–6.CrossRefPubMed
5.
Almogy G, Lieberman S, Gips M, et al. Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre. Eur J Surg Oncol. 2004;30(4):421–7.CrossRefPubMed
6.
Duan XF, Li Q. Primary hepatic angiosarcoma: a retrospective analysis of 6 cases. J Dig Dis. 2012;13(7):381–5.CrossRefPubMed
7.
Zhu YP, Chen YM, Matro E, et al. Primary hepatic angiosarcoma: a report of two cases and literature review. World J Gastroenterol. 2015;21(19):6088–96.CrossRefPubMedPubMedCentral
8.
Matthaei H, Krieg A, Schmelzle M, et al. Long-term survival after surgery for primary hepatic sarcoma in adults. Arch Surg. 2009;144(4):339–44 (discussion 344).CrossRef
9.
Molina E, Hernandez A. Clinical manifestations of primary hepatic angiosarcoma. Dig Dis Sci. 2003;48(4):677–82.CrossRefPubMed
10.
11.
Konstantinidis IT, Nota C, Jutric Z, et al. Primary liver sarcomas in the modern era: resection or transplantation? J Surg Oncol. 2018;117(5):886–91.CrossRefPubMedPubMedCentral
12.
Li DB, Si XY, Wan T, Zhou YM. A pooled analysis of treatment and prognosis of hepatic angiosarcoma in adults. Hepatobiliary Pancreat Dis Int. 2018;17(3):198–203.CrossRef
13.
Kim HR, Rha SY, Cheon SH, Roh JK, Park YN, Yoo NC. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. Ann Oncol. 2009;20(4):780–7.CrossRefPubMed
14.
Timaran CH, Grandas OH, Bell JL. Hepatic angiosarcoma: long-term survival after complete surgical removal. Am surg. 2000;66(12):1153–7.PubMed
15.
Rosales A, Que FG. Spontaneous hepatic hemorrhage: a single institution’s 16-year experience. Am Surg. 2016;82(11):1117–20.PubMed
16.
Orlando G, Adam R, Mirza D, et al. Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation—the European Liver Transplant Registry experience. Transplantation. 2013;95(6):872–7.CrossRefPubMed
17.
Park YS, Kim JH, Kim KW, et al. Primary hepatic angiosarcoma: imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization. Clin Radiol. 2009;64(8):779–85.CrossRefPubMed
18.
19.
Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69(18):7175–9.CrossRefPubMedPubMedCentral
20.
Guo T, Zhang L, Chang NE, Singer S, Maki RG, Antonescu CR. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer. 2011;50(1):25–33.CrossRef
21.
Itakura E, Yamamoto H, Oda Y, Tsuneyoshi M. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97(1):74–81.CrossRefPubMed
22.
Zietz C, Rossle M, Haas C, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol. 1998;153(5):1425–33.CrossRefPubMedPubMedCentral
23.
van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2012;379(9829):1879–86.CrossRef
24.
Painter C, Dunphy M, Anastasio E, et al. The Angiosarcoma Project: generating the genomic landscape of a rare cancer through a direct-to-patient initiative. J Clin Oncol. 2017;35(15 Suppl):1519.CrossRef
Metadata
Title
Hepatic Angiosarcoma: A Multi-institutional, International Experience with 44 Cases
Authors
Gregory C. Wilson, MD
Nuria Lluis, MD
Michael A. Nalesnik, MD
Aziza Nassar, MD
Teresa Serrano, MD
Emilio Ramos, MD
Michael Torbenson, MD
Horacio J. Asbun, MD
David A. Geller, MD
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-7062-9

Other articles of this Issue 2/2019

Annals of Surgical Oncology 2/2019 Go to the issue

Breast Oncology

Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy

ASO Author Reflections

ASO Author Reflections: The Role of Robotic Surgery in Liver Resection

Colorectal Cancer

Learning by Example: An International Perspective on Reflex-Testing for Lynch Syndrome

Pancreatic Tumors

Increased SOX9 Expression in Premalignant and Malignant Pancreatic Neoplasms

Pancreatic Tumors

Significance of 18F-Fluorodeoxyglucose (FDG) Uptake in Response to Chemoradiotherapy for Pancreatic Cancer

Colorectal Cancer

Cross-Sectional Study on MRI Restaging After Chemoradiotherapy and Interval to Surgery in Rectal Cancer: Influence on Short- and Long-Term Outcomes